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Abstract
 
The platelet plays a pivotal role in maintaining vascular integrity. In a manner similar to leuko-
cytes, platelets interact with selectins expressed on activated endothelium. P-selectin glycopro-
tein ligand 1 (PSGL-1) is the main P-selectin ligand expressed on leukocytes. Searching for
platelet ligand(s), we used a P-selectin–immunoglobulin G (IgG) chimera to affinity purify sur-
face-biotinylated proteins from platelet lysates. P-selectin–bound ligands were eluted with eth-
ylenediaminetetraacetic acid. An 
 
z
 
210-kD biotinylated protein was isolated from both human
neutrophil and platelet preparations. A band of the same size was also immunopurified from
human platelets using a monoclonal anti–human PSGL-1 antibody and could be blotted with
 
P-selectin–IgG. Under reducing conditions, both the predicted PSGL-1 
 
z
 
210-kD dimer and the
 
z
 
120-kD monomer were isolated from platelets. Comparative immunoelectron microscopy and
Western blotting experiments suggested that platelet PSGL-1 expression is 25–100-fold lower
than that of leukocytes. However, patients with chronic idiopathic thrombocytopenic purpura
who harbor predominantly young platelets displayed greater expression, indicating that PSGL-1
expression may be decreased during platelet aging. By flow cytometry, thrombin-activated
platelets from normal individuals exhibited greater expression than those unstimulated. An in-
hibitory anti–PSGL-1 antibody significantly reduced platelet rolling in mesenteric venules, as
observed by intravital microscopy. Our results indicate that functional PSGL-1 is expressed on
platelets, and suggest an additional mechanism by which selectins and their ligands participate
in inflammatory and/or hemostatic responses.
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Introduction
 
Platelets possess a wide array of glycoprotein membrane re-
ceptors that are critical for their interactions with other
platelets, the subendothelial matrix, and activated endothe-
lial cells. Both endothelial and platelet adhesion receptor
expression or activity are highly regulated and can change
within seconds. Although the unperturbed endothelium is
remarkably refractory to platelet adhesion, platelet–endo-
thelial adhesion will occur upon endothelial stimulation. In
a manner reminiscent of leukocytes, resting platelets have
been shown to roll on endothelium activated with the cal-
 
cium ionophore A23187, TNF-
 
a
 
, and after ischemia/
reperfusion injury (1–3).
Leukocyte and platelet rolling are mediated by the selec-
tin family of adhesion molecules expressed on the endothe-
lium, platelets, and leukocytes (4, 5). Two members, P- and
E-selectins, are expressed on endothelial cells. P-selectin is
stored in granules of endothelial cells and platelets and is
rapidly translocated to the cell surface after stimulation with
various secretagogues. E-selectin expression is induced by
 
Address correspondence to Paul S. Frenette, Mount Sinai School of Med-
icine, Department of Medicine, One Gustave L. Levy Pl., Box 1079,
New York, NY 10029. Phone: 212-659-9693; Fax: 212-849-2574;
E-mail: paul.frenette@mssm.edu 
1414
 
Platelet P-Selectin Glycoprotein Ligand 1
 
endotoxin or inflammatory cytokines such as IL-1 and
TNF-
 
a
 
. Endothelial selectins mediate rolling interactions
by binding counterreceptor carbohydrate ligands expressed
on the surface of leukocytes (6).
In the past few years, selectin ligands expressed on leu-
kocytes have been the subject of intense investigation (7).
The best-studied example to date is P-selectin glycoprotein
ligand 1 (PSGL-1),
 
1 
 
which was first identified on myeloid
cells. PSGL-1 is a homodimer of two disulfide-linked sub-
units of 
 
z
 
120 kD (8, 9). Molecular cloning of PSGL-1 re-
vealed a mucin-like protein with several potential sites of
O-linked carbohydrates and tyrosine sulfation (10). PSGL-1
requires both the specific glycoconjugates (sialic acid and
fucose) and the sulfated tyrosine residues for the Ca
 
2
 
1
 
-
dependent recognition by the lectin domain of P-selectin
(11, 12).
Because PSGL-1 mediates leukocyte rolling (13), it is a
good candidate to also mediate platelet rolling. However,
its presence on platelets has not been described. We show
in this report that PSGL-1 mRNA and glycoprotein are
expressed in mouse and human platelets. We also demon-
strate that a function-blocking antibody against murine
PSGL-1 can inhibit selectin-mediated platelet–endothelial
interactions in vivo.
 
Materials and Methods
 
Animals.
 
For murine platelet isolation, wild-type C57BL/6 
 
3
 
129Sv animals were used as donors. Mouse neutrophils were ob-
tained from the femoral bone marrow of wild-type or P- and
E-selectin doubly deficient mice (14). Intravital microscopy ex-
periments were performed on wild-type (C57BL/6J 
 
3
 
 129Sv)F
 
1
 
generation male mice weighing 18–22 g and aged 5–6 wk. Mice
were bred and housed at The Center for Blood Research or at
Mount Sinai School of Medicine. Experimental procedures on
animals were approved by the Animal Care and Use Committee
of The Center for Blood Research and of Mount Sinai School of
Medicine.
 
Antibodies. 
 
The P-selectin–IgG chimera (Lec
 
g
 
1 [10]), poly-
clonal rabbit anti–mouse PSGL-1 antiserum L4025, rabbit preim-
mune serum, and mouse monoclonal anti–human PSGL-1 anti-
body (PSL-275 [15]) were provided by Drs. G. Vachino and R.
Schaub (Genetic Institute, Cambridge, MA). Anti–human PSGL-1
(KPL-1) ascites fluid was a gift from Dr. G. Kansas (Northwestern
University, Chicago, IL; reference 16). Antibodies from rabbit
anti- and preimmune sera were purified with protein A–seph-
arose column (Sigma Chemical Co.) using standard procedures
(17). Rat monoclonal anti–mouse PSGL-1 4RA10 (IgG1) was
raised using recombinant PSGL-1 and recognizes the functional
19–amino acid NH
 
2
 
-terminal peptide of PSGL-1 (data not
shown). Control human IgG1 was obtained from Sigma Chemi-
cal Co., and rat IgG2a was purchased from PharMingen. The fol-
lowing antibodies were used for FACS
 
®
 
 analysis of human plate-
 
lets: anti-FC
 
g
 
RII:Fab fragment (Medarex); mAbs anti–human
PSGL-1 (PL1) and anti–P-selectin (clone CLBthromb6; both
from Immunotech); PE-conjugated anti-CD42a (Exalpha); PE-
conjugated anti-CD11b (PharMingen); and PE-conjugated anti-
CD14 (Becton Dickinson). Secondary antibody was FITC-con-
jugated sheep anti–mouse (Sigma Chemical Co.). For FACS
 
®
 
analysis of mouse platelets, rat anti–P-selectin clone RB40 (18),
PE-conjugated rat anti-CD61 clone 2C9.G2 (PharMingen), and
PE-conjugated rat anti-CD14 clone rmC5-3 (PharMingen) were
used. Secondary antibody was FITC-conjugated rabbit anti–rat
(Sigma Chemical Co.).
 
Isolation of Blood Cells.
 
Murine blood was collected from the
retroorbital venous plexus into a solution containing nine parts
HBSS (without calcium and magnesium) and one part acid citrate
dextrose (ACD; 38 mM citric acid, 75 mM Na
 
3
 
 citrate, and 100
mM dextrose). Platelet-rich plasma (PRP) was obtained by cen-
trifugation at 280 
 
g
 
 for 6 min at room temperature (RT). Platelets
were washed twice in Pipes buffer (25 mM Pipes, 137 mM
NaCl, 4 mM KCl, and 0.1% w/v dextrose, pH 7.0) containing 1
 
m
 
M prostaglandin E1 (PGE1; Sigma Chemical Co.) and counted
using a Coulter counter.
For intravital microscopy experiments, platelets were isolated
and fluorescently labeled as described previously (1, 2). In brief,
blood was collected from the retroorbital venous plexus in ACD,
and the PRP was obtained by two sequential centrifugations (280 
 
g
 
for 8 min and 280 
 
g
 
 for 3 min). Platelets were isolated by filtering
the resulting PRP through a sepharose 2B column (Sigma Chem-
ical Co.) equilibrated with Pipes buffer. Gel-filtered platelets
were fluorescently labeled with calcein-AM, 0.5 
 
m
 
g/ml (Molecu-
lar Probes).
To isolate murine neutrophils, femoral bone marrow cavities
of P- and E-selectin doubly deficient mice were flushed in RPMI
using 21-gauge needles. The cell suspension was underlayed with
Lympholyte-M (Cedarlane Laboratories) and centrifuged for 30
min at 280 
 
g
 
. Pelleted cells were washed once in RPMI. Con-
taminating erythrocytes (RBCs) were lysed in 0.8% NH
 
4
 
Cl, and
neutrophil counts were determined after three washes in Pipes
buffer.
For isolation of human platelets, human blood was drawn by
venipuncture after informed consent. PRP was obtained by cen-
trifugation of ACD-anticoagulated blood at RT (280 
 
g
 
 for 10
min). Platelets were washed and counted with a hemocytometer.
To obtain human neutrophils, blood was underlayed with Histo-
paque-1077 (Amersham Pharmacia Biotech). Pelleted cells were
resuspended to original blood volume in RPMI and mixed 30%
(vol/vol) with 6% dextran 267 (Sigma Chemical Co.). RBCs
were allowed to settle for 30 min at 37
 
8
 
C, and the excess RBCs
were lysed in NH
 
4
 
Cl. Neutrophils were washed and counted us-
ing a hemocytometer.
 
Cell Surface Labeling with Biotin.
 
Platelets (3–6 
 
3
 
 10
 
8
 
) or leu-
kocytes (2–5 
 
3
 
 10
 
7
 
) were resuspended in Pipes buffer containing
Sulfo-
 
N
 
-hydroxysulfosuccinimide–LC biotin (750 
 
m
 
g/ml; Pierce
Chemical Co.) and incubated for 30 min at RT. Platelets and
leukocytes were washed once in Pipes buffer containing PGE1 or
Pipes buffer alone, respectively.
 
Protein Preparations, Affinity Isolation, and Immunoblotting.
 
Cells
were lysed in ice-cold CHAPS ([3-cholamidopropyl-dimethyl-
ammonio]-1-propanesulfonate) buffer (3% CHAPS, 50 mM Tris
pH 7.4, 150 mM NaCl, 1 mM CaCl
 
2
 
, 1 mM MgCL
 
2
 
, 1 mg/ml
OVA, and 1 mM PMSF). Subsequent steps were carried out at
4
 
8
 
C unless otherwise indicated. Insoluble material from lysates
was pelleted at 12,000 
 
g
 
 for 10 min before preclearing with 25–50
 
m
 
l of packed protein A-sepharose (Amersham Pharmacia Bio-
 
1
 
Abbreviations used in this paper:
 
 ACD, acid citrate dextrose; FucT, fucosyl-
transferase; GPIb
 
a
 
, glycoprotein Ib
 
a
 
; HRP, horseradish peroxidase; ITP,
idiopathic thrombocytopenic purpura; PBS/BSA, PBS containing 1%
BSA; PGE1, prostaglandin E1; PRP, platelet-rich plasma; PSGL-1, P-selec-
tin glycoprotein ligand 1; RT, room temperature; V
 
crit
 
, critical velocity;
vWf, von Willebrand factor. 
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tech). Lysates, aliquoted in fractions corresponding to 
 
z
 
10
 
7
 
 leu-
kocytes and 
 
z
 
10
 
8
 
 platelets, were incubated with 25–50 
 
m
 
l of
protein A–sepharose preloaded overnight at 4
 
8
 
C, or for 1 h at RT
with 15–20 
 
m
 
g of Lec
 
g
 
1, PSL-275, or control IgG antibodies.
4RA10 antibody was loaded on agarose beads coupled with goat
anti–rat IgG (Sigma Chemical Co.) to immunoprecipitate mouse
PSGL-1. After incubation (4 h to overnight), beads were washed
five times in a washing solution containing divalent cations
(0.05% Triton X-100, 50 mM Tris-HCL pH8.3, 400 mM
NaCL, 1 mM CaCl
 
2
 
, 1 mM MgCL
 
2
 
) and two more times in a so-
lution lacking divalent cations (0.05% Triton X-100, 50 mM
Tris-HCL pH8.3, 150 mM NaCL). Proteins bound to Lec
 
g
 
1
were eluted three times with 20 
 
m
 
l of elution buffer (5 mM
EDTA; 50 mM sodium acetate pH5.2, and 0.05% Triton X-100).
Proteins immunoprecipitated by anti–PSGL-1 antibodies were
eluted in SDS sample buffer. Eluates were separated by SDS-PAGE
and transferred to polyvinylidene fluoride (PVDF) membrane
(Millipore). Membranes were blocked overnight in Tris-buffered
saline with 0.05% Tween and 4% milk. Surface-biotinylated pro-
teins were detected by incubation with horseradish peroxidase
(HRP)-conjugated neutravidin (Pierce Chemical Co.) or, in some
experiments, by incubation with Lec
 
g
 
1 (10 
 
m
 
g/ml) followed by
incubation with HRP-conjugated anti–human IgG (Pierce
Chemical Co.).
For Western blot analyses, leukocytes and platelets were lysed
in 1% Triton X-100, 0.1% SDS, 0.1% NP-40, 100 mM Tris-HCl
pH7.4, 150 mM NaCl, and 1 mM CaCl
 
2
 
 buffer. Lysates were run
on 6% SDS-PAGE, transferred on polyvinylidene fluoride mem-
branes, and blotted with KPL-1 ascites (1:5,000). Blots were de-
tected using HRP-conjugated anti–mouse IgG (Pierce Chemical
Co.).
 
Flow Cytometry.
 
Two protocols were used to evaluate PSGL-1
expression on platelets and megakaryocytic cell lines. In the first
protocol, wild-type mice were bled in ACD and PGE1 (1 
 
m
 
M,
final concentration). Platelets were isolated by gel filtration, cen-
trifuged for 6 min at 400 
 
g
 
, resuspended in PBS containing 1%
BSA (PBS/BSA), and separated in two fractions. Megakaryocytic
cells were obtained from one 10-cm
 
2
 
 tissue culture dish and
washed in PBS/BSA. To block nonspecific and FcR binding,
platelets were incubated at RT with 15 
 
m
 
g/ml of human IgG and
1:100 dilution of anti–mouse CD16/CD32 (PharMingen).
Mouse platelets were stained for 30 min at RT with a polyclonal
antibody (L4025; 50 
 
m
 
g) against murine PSGL-1 and rabbit non-
immune IgG (50 
 
m
 
g), as well as with rat monoclonal anti-murine
 
a
 
IIb
 
b
 
3 (clone D9; gift from Dr. A.K. Ng, University of Southern
Maine, Portland, ME). Platelets were washed for 6 min at 400 
 
g
 
and incubated for 30 min at RT with a goat anti–rabbit–FITC
antibody (1:200; Cappel) and goat anti–rat–PE (1:200; Sigma
Chemical Co.). Megakaryocytic cells (CMK-11/5; gift from Dr.
T. Sato, Chiba University, Chiba, Japan) were stained by succes-
sive incubations with the mAb PL1 and goat anti–mouse–PE
(Immunotech). The samples were analyzed on a FACSCalibur™
flow cytometer (Becton Dickinson), and data for 10,000 events
gated for platelets were collected.
In the second protocol, to evaluate PSGL-1 expression in both
resting and activated platelets, PRP was isolated as above, centri-
fuged, and diluted in PBS (pH 7.7, optimum for thrombin activa-
tion) at up to 50,000 human platelets per 
 
m
 
l or 25,000 mouse
platelets per 
 
m
 
l. Platelets were either left unstimulated or activated
with thrombin (0.2U/ml) for 3 min at RT in the presence of the
peptide GPRP (1.25 mM) to prevent fibrin polymerization.
Platelets were then fixed with 0.5% formaldehyde for 30 min at
RT and washed. Before the staining procedure, platelets were
 
pretreated with the mAb against Fc
 
g
 
RII at saturating concentra-
tions (20ug/ml). Staining for PSGL-1 was done with PL-1 (hu-
man platelets) or 4RA10 (mouse platelets), and P-selectin with
CLBthromb6 (human) or RB40 (mouse). FITC-conjugated sec-
ondary antibodies were used to detect PSGL-1 and P-selectin sig-
nals. For identification, platelets were also stained with PE-conju-
gated anti-CD42a (human) or anti-CD61 (mouse). To eliminate
the possibility of leukocyte contamination, human platelets were
stained with antibodies against leukocyte antigens CD11b–PE
and CD14–PE, and mouse platelets were stained with anti–
CD14–PE. The results were analyzed with CELLQuest™ soft-
ware. Relative fluorescence intensities were calculated by sub-
tracting the nonspecific binding signal of the secondary antibody
from the specific signal obtained with first and second antibodies.
 
Reverse Transcriptase PCR.
 
For reverse transcriptase PCR ex-
periments, total RNA was prepared from human gel-filtered
platelets and megakaryocytic cell lines using mRNA-Stat 60
(Tel-Test), and 0.5 
 
m
 
g was converted to cDNA using the cDNA
cycle kit (Invitrogen). For the PCR reaction, one tenth of the
reaction volume served as template for the PSGL-1 primers:
sense 5
 
9
 
ATGCTCTGCTGAGCACGGTG3
 
9 
 
and antisense
5
 
9
 
GATAGTTCTTTCTAGATTACCCCATGTTGGCCAGCT-
CCATGGTCAGC3
 
9
 
. The reaction mixture was denatured at
94
 
8
 
C for 10 min and amplified 40 cycles at 94
 
8
 
C for 1 min, 55
 
8
 
C
for 2 min, and 72
 
8
 
C for 3 min. PCR products were then ana-
lyzed on a 1% agarose gel.
 
Electron Microscopy.
 
Resting platelets were incubated with or
without 10 
 
m
 
g/ml of mouse monoclonal anti–PSGL-1 (PSL-275)
for 30 min, fixed with 1% formaldehyde for 10 min in PBS, and
attached to the surface of polylysine-coated coverslips by centrif-
ugation at 100 
 
g
 
 for 5 min. Coverslips were washed with PBS
containing 0.5% BSA pH 8.2, then incubated with 15-nm colloi-
dal gold coated with goat anti–mouse IgG for 60 min. Coverslips
were washed three times with PBS/BSA and twice with PBS,
then fixed with 1% glutaraldehyde in PBS for 10 min. Nonspe-
cific mouse IgG was used as control. The fixed platelets were
washed three times with double-distilled water just before freez-
ing. Rapid freezing of the samples was done by slamming the
coverslips onto a liquid helium–cooled copper block. Freeze dry-
ing and subsequent rotary coating was done in a Cressington
CFE-50 freeze fracture apparatus (Cressington Scientific Instru-
ments). 1.8 nm of platinum was applied at a 45
 
8
 
 angle with rota-
tion, followed by 3.5 nm of carbon at 90
 
8
 
 without rotation. Rep-
licas were recovered by separating the replica from the coverslip
using 25% hydrofluoric acid followed by 50% bleach to remove
protein, and three washes with distilled water. Replicas were
picked up on formvar-carbon–coated copper grids. Specimens
were examined and photographed in a JEOL 1200-EX electron
microscope using an accelerating voltage of 100 KV. To quanti-
tate the gold labeling density per platelet, all gold particles in ran-
domly chosen 1-
 
m
 
m
 
2
 
 areas of high magnification electron micro-
graphs were counted. This value was then multiplied by the
surface area of a platelet (14 
 
m
 
m
 
2
 
).
 
Intravital Microscopy and Image Analysis.
 
Fluorescently labeled
gel-filtered platelets were incubated at RT for 10 min with either
4RA10 antibody (1 mg/kg, weight of recipient mouse) or rat
IgG2b control. The platelet-rich suspension with the antibody
was injected through the tail vein into wild-type (C57BL/6 
 
3
 
129Sv)F
 
1
 
 generation recipient mice. Mice were anesthetized with
2.5% tribromoethanol 0.15 ml/10 g and prepared for intravital
microscopy of the mesentery as described previously (2). Venules
were activated by superfusion of calcium ionophore A23187 (30
 
ml of 10 mM solution in PBS). One venule per animal was re-1416 Platelet P-Selectin Glycoprotein Ligand 1
corded for 20 min. Centerline erythrocyte velocity, venular shear
rates, and critical velocities (Vcrit) were determined as described
previously (2). Quantitation of platelet–endothelial interactions
was done by an investigator blind to the studied groups. Platelets
traveling for a distance $30 mm at a velocity slower than Vcrit
were scored as “rolling.” Any interaction of a platelet with the
endothelium occurring at a velocity slower than Vcrit was consid-
ered to be “tethering.” The average number of tethering or roll-
ing platelets per minute over a venular segment of 250 mm was
determined by taking the average of 10 counts of 1 min (five in
each half of filming). The number of platelets that were captured
but not rolling on the venular wall was obtained by subtracting
“rolling” from “tethering.”
Results
PSGL-1 mRNA and Protein Are Expressed in Platelets.
Because PSGL-1 is the main ligand for P-selectin on my-
eloid cells, we investigated whether it is also expressed by
platelets (Fig. 1). We first evaluated the presence of PSGL-1
mRNA. Total RNA was extracted from gel-filtered hu-
man platelets and from two megakaryocytic cell lines
(CMK-86 and CMK-11/5 [19]). After reverse transcrip-
tion, DNA was amplified using primers from the signal se-
quence and the sequence encoding amino acids 83–92 of
the mature polypeptide. A predicted 360-bp PCR product
was obtained from human platelet preparations. The same
product could also be amplified from the two human
megakaryocytic cell lines (Fig. 1 B), suggesting that it does
not result from leukocyte contamination of our platelet
preparation. To investigate whether PSGL-1 protein is ex-
pressed on the surface of platelets, we double stained mu-
rine platelets with purified rabbit anti–PSGL-1 or non-
immune purified rabbit IgG, and with an antibody
recognizing the integrin aIIbb3. As shown in Fig. 1 A, a sig-
nificant shift in the fluorescence was seen when unstimulated
murine platelets were incubated with purified polyclonal
anti–mouse PSGL-1 compared with purified preimmune
IgG. In addition, we also stained one megakaryocytic cell
line (CMK-86) with the monoclonal anti–PSGL-1 (PL1)
and observed a slight but significant shift in the level of
fluorescence (Fig. 1 C). These results suggest that PSGL-1
is expressed on platelets and megakaryocytes, but did not
show whether it was biologically active.
Platelet PSGL-1 Can Bind P-Selectin. To evaluate whether
the PSGL-1 expressed on platelets can bind P-selectin, we
affinity isolated selectin ligands using a modified protocol
used for isolation of selectin ligands on myeloid cell lines
(20). Platelets and control neutrophils were isolated, sur-
face biotinylated with Sulfo-N-hydroxysulfosuccinimide–
LC biotin, and lysed in CHAPS buffer. P-selectin ligands
were affinity isolated by incubating cell lysates with pro-
tein A–sepharose beads preincubated with P-selectin–IgG.
Specifically bound proteins were eluted with EDTA and
electrophoresed on SDS-PAGE. Alternatively, immuno-
precipitations from lysates of the same preparation were
carried out using anti–PSGL-1 antibodies.
As depicted in Fig. 2 A, an z210-kD biotinylated pro-
tein was affinity isolated with P-selectin–IgG from both
neutrophil and platelet preparations. No biotinylated pro-
teins were eluted from beads covered with control human
IgG1 (not shown). A band of the same size was immu-
nopurified with a mouse monoclonal anti–human PSGL-1
antibody (PSL-275) from both platelet (Fig. 2 A, lane 3)
and neutrophil (not shown) lysates. When EDTA eluate
Figure 1. PSGL-1 expression in platelets and megakaryocytic cell lines. (A) For flow cytometry, mouse platelets were double labeled with the mAb D9
against mouse aIIbb3 and with the polyclonal antibody L4025 against mouse PSGL-1, or with preimmune rabbit IgG. (B) For reverse transcriptase
PCR, total RNA was prepared from gel-filtered human platelets and from two human megakaryocytic cell lines, CMK-86 and CMK-11/5. After cDNA
conversion, a fragment of expected length was amplified by PCR using primers from human PSGL-1 sequence. (C) PSGL-1 expression on CMK-11/5
evaluated by flow cytometry. CMK-11/5 cells were labeled with the mAb PL1 directed against human PSGL-1 (open area) or with preimmune mouse
IgG (filled area). FSC-H, forward scatter; SSC-H, side scatter.1417 Frenette et al.
was run under reducing conditions (Fig. 2 C), both the
monomeric (z120 kD) and dimeric forms were detected.
In another set of experiments, Fig. 2 B, PSGL-1 was im-
munopurified with PSL-275 antibody and electropho-
resed, and the blot was incubated with P-selectin–IgG.
Again, an z210-kD band was detected, indicating that
PSGL-1 is indeed expressed in its functional form on hu-
man platelets.
PSGL-1 Expression on Platelets Varies and Is Lower Than
on Leukocytes. To estimate the copy number of PSGL-1
molecules on normal platelets and to assess expression in a
disease state, we evaluated PSGL-1 expression using West-
ern blot analyses of leukocyte and platelet lysates from nor-
mal individuals and patients with chronic idiopathic
thrombocytopenic purpura (ITP). As platelets from these
patients have a very short life span, the majority of circu-
lating platelets at any given time are young. In each prepa-
ration, the numbers of contaminating leukocytes were de-
termined using a hemocytometer and were estimated to
represent z1–6 3 104 leukocytes per load of platelet ly-
sate. Leukocyte contamination of ITP platelet preparations
was not higher than preparations from normal individuals.
Dilutions of leukocyte lysates were run along with those of
platelets. As shown in Fig. 3, a mAb to PSGL-1 (KPL-1)
detected a strong signal when lysates from 2 3 106 leuko-
cytes were loaded, but no signal was detected when leuko-
cyte numbers in the range of those contaminating platelet
preparations were analyzed (2 3 104 leukocytes). Lysates
from 2 3105 leukocytes showed a faint or no signal (not
shown). KPL-1 detected a faint signal only when at least
109 normal platelets were loaded. In contrast, a strong sig-
nal for PSGL-1 dimer was detected in platelet lysates con-
taining 2.5 3 108 platelets from either of two patients with
chronic ITP. These patients were splenectomized and
moderately thrombocytopenic (counts 60,000 per ml and
90,000 per ml). These data indicate that PSGL-1 copy
numbers are low in normal platelets compared with leuko-
cytes and appear to be greater in platelets from chronic
ITP patients. The results suggest that platelets may be het-
erogeneous in PSGL-1 expression, and that perhaps
PSGL-1 is lost during platelet aging.
To evaluate surface expression of PSGL-1 in activated
platelets and to further demonstrate that the observed
PSGL-1 does not stem from contaminating leukocytes, we
stained human platelets with the mAb PL-1 and with anti-
bodies to two leukocyte antigens (CD11b and CD14) be-
fore and after activation with thrombin (0.2 U/ml). The
preparations were also stained with anti-aIIbb3 to specifi-
cally gate on platelets by FACS® analysis. The level of flu-
orescence of PSGL-1 in aIIbb3-expressing cells (human
platelets) increased on average threefold in three indepen-
dent donors (Fig. 4 A). Similar results were obtained after
staining murine platelet with 4RA10 mAb, which can in-
Figure 2. Affinity isolation of PSGL-1 glycoprotein
from platelets and neutrophils. (A) Purified prepara-
tions of neutrophils or platelets were biotinylated and
lysed. Cell lysates were incubated with P-selectin–IgG
(P-sel-IgG) chimera or anti–PSGL-1 (PSL-275). Spe-
cifically bound proteins were eluted and separated on
7.5% SDS gel under nonreduced conditions. (B)
PSGL-1 was immunopurifed from neutrophil and
platelet lysates. SDS-eluted proteins were analyzed on
7.5% SDS gel. The blotted proteins were detected with
P-selectin–IgG and HRP-conjugated anti–human IgG.
(C) Biotinylated platelets were lysed and subjected to
affinity isolation with P-selectin–IgG (P-sel-IgG). The
high molecular weight complex (*) seen in the nonre-
duced (NR) sample likely represents a disulfide-
bonded multimer formed during platelet lysis through
exposure of free sulfhydryl from the transmembrane
and the cytoplasmic domains of PSGL-1. Note that the
major species observed in the reduced lane (R) is of the
expected size 120 kD for PSGL-1 monomer (arrow).
The numbers on the side indicate migration of marker
proteins in kD.
Figure 3. Comparison of expression levels of PSGL-1 on leukocytes
and platelets from normal subjects and patients with chronic ITP. Leuko-
cytes and platelets were lysed, and proteins were separated on 6% SDS gel,
transferred, and blotted with KPL-1. A depicts a Western blot from a nor-
mal donor, and B shows a patient with chronic ITP. Lanes 1 and 5 were
from 2 3 106 leukocytes, lanes 2 and 6 were from 2 3 104 leukocytes,
lanes 3 and 4 were from 108 and 109 platelets, respectively, and lane 7 was
from 2.5 3 108 platelets. The level of expression of PSGL-1 from ITP
platelets appears higher than that of normal volunteer platelets.1418 Platelet P-Selectin Glycoprotein Ligand 1
hibit PSGL-1 function (Fig. 4 B). The low level of fluores-
cence of CD11b (Mac1) and CD14 did not increase, sug-
gesting that the PSGL-1 signal indeed did not originate
from leukocytes. Our results also suggest that there is a sig-
nificant intracellular pool of PSGL-1 that can be mobilized
after thrombin activation.
Immunolocalization of PSGL-1 on Platelets. Unlike
platelets, leukocytes display numerous cell surface mi-
crovilli, which are thought to be the initial contact site
with the microvascular endothelium. In support of a role
for microvilli in leukocyte rolling, adhesion molecules in-
volved in this activity, including PSGL-1, localized pri-
marily on these processes (21, 22). To immunolocalize
PSGL-1 on platelets, we performed anti–mouse IgG im-
munogold staining of freshly isolated resting platelets using
either a mouse mAb to human PSGL-1 (PSL-275) or a
control nonspecific IgG. As shown in Fig. 5 B, the anti–
PSGL-1 gold particles clearly label the surface of human
resting platelets. Gold label was randomly dispersed across
the cell surface. No labeling was seen when the primary
antibody was replaced by an isotype-matched IgG control
(Fig. 5 A). The gold particles were not clustered, suggest-
ing a stoichiometry near 1:1 between particle and anti-
body. Therefore, the number of PSGL-1 molecules may
be estimated by counting the number of gold particles. On
average, each 1 mm2 contained 81 6 21 gold particles
(mean 6 SD, n 5 10), indicating that each platelet would
have on average 1,134 gold particles (81 3 14 mm2). As
P-selectin binding sites were estimated to be z25,000 per
neutrophil (23), the above Western blot (Fig. 3) and electron
microscopy (Fig. 5) analyses suggest that platelets may harbor
z25–100-fold fewer PSGL-1 molecules than leukocytes.
PSGL-1 Mediates Platelet–Endothelial Interactions In Vivo.
To investigate whether PSGL-1 was mediating the pre-
viously observed platelet rolling (1), we tested whether
an inhibitory rat mAb (4RA10) against mouse PSGL-1
would influence platelet–endothelial interactions in vivo.
To this end, gel-filtered wild-type platelets were labeled
with calcein-AM, incubated with either 4RA10 or rat iso-
type-matched IgG, and transfused into wild-type mice.
Mice were immediately prepared for intravital micros-
copy. After treatment of the mesentery with calcium iono-
phore A23187, we observed a fourfold reduction in the
numbers of rolling platelets that were pretreated with anti–
PSGL-1 compared with platelets treated with isotype-
matched IgG control (Fig. 6 A). Furthermore, 4RA10
antibody administration reduced the numbers of platelets
interacting without meeting our criteria for rolling (“cap-
tured;” Fig. 6 B). The two treatment groups displayed
similar hemodynamic characteristics (Table I). As ex-
pected, anti–PSGL-1 treatment also completely inhibited
leukocyte rolling in the same venules (data not shown).
Our data indicate that PSGL-1 participates in platelet–
endothelial interactions in vivo.
Figure 4. Flow cytometry of unstimulated and throm-
bin-activated platelets. Platelets were fixed in 0.5% formal-
dehyde as either not actively stimulated or thrombin-stim-
ulated (0.2 U/ml) platelets. (A) Human platelets were
double stained with anti–P-selectin, anti–PSGL-1, anti-
CD11b, or anti-CD14 and with anti-aIIbb3. (B) Mouse
platelets were double stained with anti-aIIbb3 and anti–
P-selectin, or anti–PSGL-1 or anti-CD14. The data are ex-
pressed as relative fluorescence intensity, which means that
the nonspecific binding signal of the secondary antibody
was subtracted from the specific signal obtained with first
and second antibody. n 5 3, different healthy individuals or
mice; *P , 0.05; **P , 0.01 compared with unstimulated.1419 Frenette et al.
Figure 5. Immunogold label-
ing of resting platelets. (A) Elec-
tronmicrograph shows a repre-
sentative platelet at rest treated
with nonspecific mouse IgG. In
B, PSGL-1 receptors were la-
beled with PSGL-1 specific mono-
clonal IgG and 15-nm colloidal
gold particles coated with goat
anti–mouse IgG as described.
PSGL-1 specific gold particles are
randomly distributed on the cell
surface. Bar 5 100 nm.
Figure 6. Platelet–endothelial interactions in
secretagogue-stimulated mesenteric venules. Wild-
type gel-filtered fluorescently labeled platelets were
incubated with either isotype-matched IgG control
or with an inhibitory anti–PSGL-1 (4RA10), and
were injected into wild-type recipient mice. After
the preparation of the mesentery, 30–40-mm
venules were activated with the secretagogue
A23187, and platelet–endothelial interactions were
recorded for 20 min. (A) number of rolling platelets
per minute. n 5 7; P , 0.001. (B) number of cap-
tured platelets per minute. n 5 7; P , 0.02.1420 Platelet P-Selectin Glycoprotein Ligand 1
Discussion
In the microcirculation, the inflammatory response to an
injury occurs almost simultaneously with the onset of he-
mostasis. In this respect, hemostasis may be considered a
special event of inflammation, and thus platelets may be
considered special inflammatory cells. Indeed, platelet ad-
hesion to the endothelium is an early event during inflam-
mation, and it has been known for years that both neutro-
phils and platelets accumulate together in the inflamed
tissue (24). This study describes one mechanism by which
platelets interact with the endothelium and eventually fulfill
their potential as inflammatory cells and/or protectors of
endothelial integrity.
Based on our previous studies, we know that the rolling
of resting platelets on activated endothelium is dependent
on endothelial P-selectin (1, 2). This result suggested that
platelets constitutively express a counterreceptor(s) for en-
dothelial selectins. We have now identified on platelets the
presence of functional PSGL-1, the most physiologically
relevant selectin ligand identified so far (13, 25, 26). Several
lines of evidence indicate that PSGL-1 expression was en-
dogenous to platelets/megakaryocytes and was not the re-
sult of contaminating leukocytes: (a) two human mega-
karyocytic cell lines, which could not contain any
leukocytes, were shown to express PSGL-1 (Fig. 1, B and
C); (b) the low level of leukocyte contamination was
checked and found to be similar in all platelet preparations,
but the platelets prepared from ITP patients presented
much higher levels of PSGL-1 (Fig. 3); (c) activation of pu-
rified platelets led to a two- to fourfold increase in PSGL-1
surface expression, whereas surface expression of leukocyte
antigens did not change (Fig. 4); and (d) anti–PSGL-1 in-
hibited single platelet rolling as observed by intravital mi-
croscopy (Fig. 6).
First we were able to identify PSGL-1 on human plate-
lets by reverse transcriptase PCR, and on murine platelets
by flow cytometry. Previous studies that analyzed PSGL-1
expression in various human tissues found its expression to
be largely restricted to hematopoietic cells, but no expres-
sion was detected in megakaryocytes (27) or platelets (28).
However, the methods used in these studies may not have
been sensitive enough to detect low levels of expression. As
suggested by our electron microscopy and Western blot
analyses, the expression level of PSGL-1 on normal plate-
lets indeed appears to be one or two orders of magnitude
lower than on leukocytes. Interestingly, platelets from pa-
tients with chronic ITP display greater copy numbers of
PSGL-1. ITP is an immune disease characterized by accel-
erated platelet clearance. Because of the short platelet life
span in chronic ITP, patients with this disorder harbor pre-
dominantly young platelets. Although the mechanism re-
sponsible for the greater PSGL-1 expression in chronic ITP
remains to be elucidated, it is possible that higher expres-
sion occurs in young platelets and that the glycoprotein
might be lost during aging. Surprisingly, in vitro platelet
stimulation with thrombin further increased surface expres-
sion of PSGL-1. Whether PSGL-1 is stored in intracellular
granules and whether this upregulation translates into en-
hanced platelet–endothelial interactions remains unclear.
However, our previous study suggested that exogenous
thrombin stimulation of platelets lacking P-selectin does
not increase their interactions with activated endothelium
in vivo (1). It is possible that surface expression of PSGL-1
might be modulated in vivo. This appears to be the case for
P-selectin, which is shed from activated platelets. This oc-
curs within the first hour after reinfusion of thrombin-
treated platelets in primates (29) and mice (30), without al-
terations in platelet half-life.
It is also noteworthy that the presence of PSGL-1 on a
particular cell type does not necessarily indicate its func-
tional relevance. For example, most lymphocytes express
PSGL-1, but only 10–20% are actually able to bind P-selec-
tin (15). To bind P-selectin, PSGL-1 needs to be posttrans-
lationally modified by protein glycosylation and tyrosine
sulfation (7). Therefore, it was important to investigate
whether platelet PSGL-1 has the ability to bind P-selectin.
We were able to isolate PSGL-1 from neutrophil and plate-
let cell lysates using a P-selectin–IgG chimera, indicating
that platelet PSGL-1 carries elements required for P-selec-
tin recognition. The binding was Ca21 dependent, suggest-
ing that PSGL-1 recognition is through the lectin domain.
Furthermore, we confirmed the functionality of platelet
PSGL-1 as a ligand for P-selectin in an in vivo model. Us-
ing intravital microscopy, we found a significant reduction
in platelet interactions with activated endothelium when
platelets were preincubated with an antibody against
PSGL-1 (Fig. 6). This important but only partial inhibition
of platelet rolling differs from the complete inhibition of
leukocyte rolling observed with the same antibody in the
same venules. This result suggests that another ligand exists
that may participate in the interactions of platelets with en-
dothelial P-selectin. The platelet receptor for von Wille-
brand factor (vWf), the glycoprotein Iba (GPIba), was
shown recently to interact with P-selectin. Cells expressing
GPIba can roll on P-selectin, and cells expressing P-selec-
tin are able to bind to immobilized glycocalycin (31), the
GPIba fragment containing binding sites for vWf and
thrombin. Similar to PSGL-1, GPIba is a tyrosine-sulfated
sialomucin that contains a cleavage site for mocarhagin, a
protease from the venom of the Mozambiquan spitting co-
bra. Interestingly, mocarhagin cleavage of PSGL-1 abro-
gates P-selectin binding (32). There are also similarities be-
Table I. Hemodynamic Characteristics of Venules
Antibody
treatment Venular size
Centerline
velocity Shear rate
mm mm/s s21
Control IgG 29.3 6 1.0 3.2 6 0.7 524 6 94
anti–PSGL-1 31.9 6 2.0 2.6 6 0.2 414 6 55
Seven mice per group. There was no statistical difference between the
two groups. 1421 Frenette et al.
tween the ligands for GPIba and PSGL-1: vWf and P-selectin
are stored together in the a-granules of platelets and the
Weibel-Palade bodies of endothelial cells (33), and their
surface expression is thus tightly linked. Whether an inter-
action between endothelial P-selectin and platelet GPIba
accounts for the remaining platelet rolling not inhibited by
anti–PSGL-1 has yet to be investigated.
It has been demonstrated previously that a(1,3)fucosyl-
transferases (FucTs), FucT IV and FucT VII, are required
for synthesis of leukocyte selectin ligands. It is noteworthy
that platelets lacking FucT IV and VII interacted as well as
wild-type platelets with TNF-a–inflamed venules of
P-selectin knockouts (rolling is E-selectin dependent under
these conditions), suggesting that the platelet E-selectin
ligand differs, at least at the level of posttranslational modi-
fications, from its leukocyte counterpart (2). Whether
PSGL-1 can mediate leukocyte or platelet rolling on E-selec-
tin is unknown. Although the glycosylation of platelet
PSGL-1 has not been evaluated, it is possible that other
FucTs in the megakaryocyte may account for the posttrans-
lational modifications necessary to confer P-selectin bind-
ing. Six different FucTs have been cloned so far (34, 35). In
addition, the ligands used by platelets to bind activated en-
dothelium may also depend on the shear within the vessel.
Our group has preliminary evidence that, at very low shear
rates (z200s 21), platelets preferentially use vWF to trans-
locate on stimulated venular endothelium (André, P., and
D.D. Wagner, unpublished observations). vWF was shown
to mediate platelet rolling and/or translocation in vitro
(36). Thus, depending on conditions, platelets may roll on
either component of the Weibel-Palade body.
In conclusion, we have identified PSGL-1 on platelets,
and we have demonstrated that it is functional in mediating
platelet–endothelium interaction. Although the biological
significance of these interactions remains to be elucidated, a
platelet behavior analogous to that of leukocytes suggests
broader roles than a function restricted to hemostasis. This
concept is supported by recent observations of platelet in-
volvement in injury caused by ischemia/reperfusion (3, 37)
and perhaps angiogenesis (38). The intricate interrelation
between inflammation and thrombosis is further reinforced
by the recent finding that soluble PSGL-1 can accelerate
thrombolysis and prevent reocclusion in vivo (39). More
studies are needed to dissect the respective roles of each
molecular player in these different pathways.
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